US Department of Veterans Affairs to Trial GLP-1 Drug for Alcohol Use Disorder

The U.S. Department of Veterans Affairs announced a clinical trial to test injectable semaglutide as a treatment for alcohol use disorder in veterans [1, 2].

This trial represents a significant shift in addiction treatment by exploring whether medications originally designed for diabetes and weight loss can address substance abuse. Alcohol use disorder is a longstanding challenge within the military and veteran community, often requiring multifaceted medical interventions [1, 4].

Semaglutide is a GLP-1 medication that has gained widespread attention for its role in metabolic health ^[2]. The VA said it intends to use the drug to determine if it can effectively curb alcohol cravings or consumption patterns in its patient population [1, 4].

The study will take place at various Department of Veterans Affairs facilities across the United States [1, 5]. By leveraging the existing infrastructure of the VA healthcare system, researchers aim to gather data on the safety and efficacy of the injectable drug specifically for those struggling with alcohol dependency [1, 5].

The announcement of the trial occurred on Thursday, as reported in early March 2026 [2, 3]. The initiative follows a growing body of research into how GLP-1 receptor agonists affect the brain's reward system, a mechanism central to the cycle of addiction [2, 4].

While the VA has not released specific enrollment numbers or a projected timeline for the results, the trial focuses on the potential for pharmaceutical intervention to supplement traditional therapy, and support groups [1, 5].